GoAI
Get started
Wuhan YZY Biopharma Co Ltd logo

Wuhan YZY Biopharma Co Ltd

2496.HK

HKSEHealthcareBiotechnology

Open in GoAI

Latest quote

HK$3.60

HK$0.00 · 0.00%

Aug 13, 1:34 PM HKTData delayed

2496.HK company overview

Historical prices · Market data may be delayed.

Company profile

Company website

Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic conditions. The company's extensive portfolio of drug candidates aims to address a wide range of diseases, such as malignant ascites, malignant pleural effusion, various solid tumors (including pancreatic cancer, hepatocellular carcinoma, other advanced solid tumors, and HER2-positive solid tumors), small cell lung cancer, and relapsed/refractory multiple myeloma. Additionally, they are advancing therapies for COVID-19 and several eye disorders like wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and other conditions characterized by abnormal blood vessel formation in the eye. The company, established in 2010, is headquartered in Wuhan, China.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CN
CEO
Pengfei Zhou
Listed since
Sep 26, 2023
Employees
106

Market position

52-week range

Current HK$3.60

Open
HK$3.60
Previous close
HK$3.60
Volume
200
0.01× average
Average volume
22.73K
Average daily volume
Market cap
722.59M HKD
Beta
0.5
Market reference 1
50-day average
HK$3.7954
-5.15% below average
200-day average
HK$5.6256
-36.01% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-6.2×
P/B (TTM)
-11.26×
P/S (TTM)
7.3×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
16.27%
Operating margin
-116.86%
Net margin
-114.69%

Financial health

Debt / equity
-2.41×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends945%-2434%-5813%-9191%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 78.90%Gross margin, FY2025: 9.48%Operating margin, FY2021: -1085.82%Operating margin, FY2022: -7759.22%Operating margin, FY2023: -1487.69%Operating margin, FY2024: -90.90%Operating margin, FY2025: -135.02%Net margin, FY2021: -1219.61%Net margin, FY2022: -8346.50%Net margin, FY2023: -1601.92%Net margin, FY2024: -90.53%Net margin, FY2025: -126.73%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 78.90%. Gross margin FY2025 9.48%. Operating margin FY2021 -1085.82%. Operating margin FY2022 -7759.22%. Operating margin FY2023 -1487.69%. Operating margin FY2024 -90.90%. Operating margin FY2025 -135.02%. Net margin FY2021 -1219.61%. Net margin FY2022 -8346.50%. Net margin FY2023 -1601.92%. Net margin FY2024 -90.53%. Net margin FY2025 -126.73%.

Income trends

Revenue

65.13M HKD-39.59%

Operating income

−87.93M HKD+10.27%

Net income

−82.54M HKD+15.43%
Income trends across reported periods137.69M HKD18.17M HKD−101.34M HKD−220.86M HKDRevenue, FY2021: 12.18M HKDRevenue, FY2022: 2.26M HKDRevenue, FY2023: 11.92M HKDRevenue, FY2024: 107.81M HKDRevenue, FY2025: 65.13M HKDOperating income, FY2021: −132.23M HKDOperating income, FY2022: −175.58M HKDOperating income, FY2023: −177.37M HKDOperating income, FY2024: −98M HKDOperating income, FY2025: −87.93M HKDNet income, FY2021: −148.52M HKDNet income, FY2022: −188.87M HKDNet income, FY2023: −190.98M HKDNet income, FY2024: −97.6M HKDNet income, FY2025: −82.54M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 12.18M HKD. Revenue FY2022 2.26M HKD. Revenue FY2023 11.92M HKD. Revenue FY2024 107.81M HKD. Revenue FY2025 65.13M HKD. Operating income FY2021 −132.23M HKD. Operating income FY2022 −175.58M HKD. Operating income FY2023 −177.37M HKD. Operating income FY2024 −98M HKD. Operating income FY2025 −87.93M HKD. Net income FY2021 −148.52M HKD. Net income FY2022 −188.87M HKD. Net income FY2023 −190.98M HKD. Net income FY2024 −97.6M HKD. Net income FY2025 −82.54M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue65.13M HKD107.81M HKD11.92M HKD2.26M HKD12.18M HKD
Cost of goods sold58.95M HKD22.74M HKD———
Gross profit6.17M HKD85.07M HKD11.92M HKD2.26M HKD12.18M HKD
Research and development73.24M HKD164.99M HKD154.47M HKD157.33M HKD112.89M HKD
Selling, general, and administrative20.87M HKD14.9M HKD22.23M HKD20.53M HKD31.5M HKD
Operating expenses94.11M HKD183.07M HKD177.37M HKD177.85M HKD144.39M HKD
Interest income739.36K HKD2.57M HKD1.34M HKD283K HKD162K HKD
Interest expense4.82M HKD4.08M HKD2.39M HKD2.47M HKD14.97M HKD
Depreciation and amortization4.28M HKD6.57M HKD6.39M HKD6.34M HKD7.03M HKD
Operating income−87.93M HKD−98M HKD−177.37M HKD−175.58M HKD−132.23M HKD
Net income−82.54M HKD−97.6M HKD−190.98M HKD−188.87M HKD−148.52M HKD

Company facts updated Aug 24, 2026.

2496.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$195.4

-5.05%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.50

-3.53%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$220.2

-3.42%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.30

-5.29%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$98.90

-3.42%

Continue in GoAI

Research 2496.HK

research.disclaimer